Corbus Pharmaceuticals Completes Enrollment in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis

Ads

You May Also Like

Immune Therapeutics, Inc. Announces Engagement of Maxim Group LLC to Provide Strategic Advisory Services

ORLANDO, Fla., June 15, 2016 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN), a clinical-stage biotech ...

Rexahn Announces $10 Million Registered Direct Offering

ROCKVILLE, Md., June 07, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) today ...